The different approaches used by InveniAI to disrupt the status quo and solve complex problems in Healthcare, Drug Discovery & Development applications are exemplified in its EvolverAI and PharmGPS® platforms.
EvolverAI is InveniAI's augmented intelligence platform that combines human intuition based on experience and expertise with the comprehensiveness and scale of artificial intelligence. EvolverAI combines Big Data technology with machine learning to present to human experts massive and complex data sets in a manner that allow us humans to decipher patterns and enables the generation of hypotheses. EvolverAI combines the tenets of deductive, inductive and abductive research in this journey of discovery.
PharmGPS® is InveniAI's Big Data platform applied to understanding how drugs work and which of them are useful in satisfying unmet medical needs. PharmGPS® has collated and crystallized the cumulative wisdom of pharmaceutical and drug development research to identify the drugs that are most likely to succeed in the regulatory process and satisfy patients’ needs. It utilizes machine learning and big data approaches to predict future potential of drugs that are still in early stages of clinical development.
- Software as a Service / AI as Service (SaaS, AIaaS)
- Drug Repurposing
No mentions found
Posts Mentioning This Company
Big Data to Therapeutic Leads
EvolverAI presents the knowledge in the context of a broad question and allows us to search for other questions which …
Take the Next Step in the Path Towards Success in Drug Development
PharmGPS assesses the current relative performance of drugs in development and predicts the immediate future performance of these drugs with …
No services posted yet
No clinical trials found
No patents found
No publications found
Assets (therapeutic products)
No assets found
|Year||Partner||Focus||Amount of Deal|
(2018, Jan. 1)
|Kyowa Hakko Kirin||Kyowa Hakko Kirin, a life sciences company with a focus on new biologics and medicines for unmet medical needs, will leverage InveniAI’s platform – AlphaMeld™ – to maximize portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications.||--|